<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/23D04EC2-3A05-4711-B472-F29894825709"><gtr:id>23D04EC2-3A05-4711-B472-F29894825709</gtr:id><gtr:name>Institute of Zoology</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9F83FD31-5C58-4A50-8F95-F016830D1F58"><gtr:id>9F83FD31-5C58-4A50-8F95-F016830D1F58</gtr:id><gtr:name>McGill University Health Center</gtr:name><gtr:address><gtr:line1>McGill University Health Center</gtr:line1><gtr:line2>3640 University Street</gtr:line2><gtr:postCode>H3A 2B2</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D7896884-A15E-47EC-9387-FD575B3B6607"><gtr:id>D7896884-A15E-47EC-9387-FD575B3B6607</gtr:id><gtr:name>Netherlands Institute for Neuroscience</gtr:name><gtr:address><gtr:line1>Meibergdreef 47</gtr:line1><gtr:postCode>1105 BA</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F06E2300-1034-4556-912C-36C6D454F922"><gtr:id>F06E2300-1034-4556-912C-36C6D454F922</gtr:id><gtr:name>California Institute of Technology</gtr:name><gtr:address><gtr:line1>1200 East California Boulevard</gtr:line1><gtr:postCode>91125</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7A0397DD-E0C6-4EA3-8031-B841D2503C4D"><gtr:id>7A0397DD-E0C6-4EA3-8031-B841D2503C4D</gtr:id><gtr:name>Royal Holloway, University of London</gtr:name><gtr:address><gtr:line1>Egham Hill</gtr:line1><gtr:line4>Egham</gtr:line4><gtr:line5>Surrey</gtr:line5><gtr:postCode>TW20 0EX</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2E8E7A84-3BC7-4739-986D-C05FC31789B8"><gtr:id>2E8E7A84-3BC7-4739-986D-C05FC31789B8</gtr:id><gtr:name>Charit? - University of Medicine Berlin</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2F14C09D-4C02-4D36-B564-2A79485D1625"><gtr:id>2F14C09D-4C02-4D36-B564-2A79485D1625</gtr:id><gtr:name>International Spinal Research Trust (Spinal Research)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Wolfson Centre for Age Related Diseases</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/23D04EC2-3A05-4711-B472-F29894825709"><gtr:id>23D04EC2-3A05-4711-B472-F29894825709</gtr:id><gtr:name>Institute of Zoology</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9F83FD31-5C58-4A50-8F95-F016830D1F58"><gtr:id>9F83FD31-5C58-4A50-8F95-F016830D1F58</gtr:id><gtr:name>McGill University Health Center</gtr:name><gtr:address><gtr:line1>McGill University Health Center</gtr:line1><gtr:line2>3640 University Street</gtr:line2><gtr:postCode>H3A 2B2</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D7896884-A15E-47EC-9387-FD575B3B6607"><gtr:id>D7896884-A15E-47EC-9387-FD575B3B6607</gtr:id><gtr:name>Netherlands Institute for Neuroscience</gtr:name><gtr:address><gtr:line1>Meibergdreef 47</gtr:line1><gtr:postCode>1105 BA</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F06E2300-1034-4556-912C-36C6D454F922"><gtr:id>F06E2300-1034-4556-912C-36C6D454F922</gtr:id><gtr:name>California Institute of Technology</gtr:name><gtr:address><gtr:line1>1200 East California Boulevard</gtr:line1><gtr:postCode>91125</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7A0397DD-E0C6-4EA3-8031-B841D2503C4D"><gtr:id>7A0397DD-E0C6-4EA3-8031-B841D2503C4D</gtr:id><gtr:name>Royal Holloway, University of London</gtr:name><gtr:address><gtr:line1>Egham Hill</gtr:line1><gtr:line4>Egham</gtr:line4><gtr:line5>Surrey</gtr:line5><gtr:postCode>TW20 0EX</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2E8E7A84-3BC7-4739-986D-C05FC31789B8"><gtr:id>2E8E7A84-3BC7-4739-986D-C05FC31789B8</gtr:id><gtr:name>Charit? - University of Medicine Berlin</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2F14C09D-4C02-4D36-B564-2A79485D1625"><gtr:id>2F14C09D-4C02-4D36-B564-2A79485D1625</gtr:id><gtr:name>International Spinal Research Trust (Spinal Research)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/418AD2D5-33F6-47B7-B374-BA224E2C4309"><gtr:id>418AD2D5-33F6-47B7-B374-BA224E2C4309</gtr:id><gtr:firstName>Elizabeth</gtr:firstName><gtr:otherNames>Jane</gtr:otherNames><gtr:surname>Bradbury</gtr:surname><gtr:orcidId>0000-0003-4252-0234</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1002055"><gtr:id>3966C828-4EB0-4001-9DCA-9E8587F55709</gtr:id><gtr:title>Acute and chronic spinal cord injury: novel studies of synaptogenesis, plasticity and mechanisms of repair</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1002055</gtr:grantReference><gtr:abstractText>Spinal cord injury (SCI) leads to severe disability, but in nearly all cases there is some recovery in function over the first year following injury. We intend to find out more about these spontaneous recovery processes in order to try and develop therapies to increase the extent of recovery. For example, using special recording techniques we will study changes in nerve fibre conduction at early and late stages following SCI to see when conduction is compromised and how this changes over time. We have an enzyme therapy which can dissolve molecules that are present in SCI scar tissue. We need to optimise ways of delivering large amounts of this enzyme to the spinal cord while minimising the trauma of repeated administration. We have a new way of delivering the enzyme so that it gets into cells at the spinal cord scar, where it is most needed, and we will test whether this can improve function. We will also use novel techniques to show whether new fibres that have sprouted following this therapy can transmit signals to other nerve cells by studying nerve cell connectivity using special fluorescent probes that light up only when there is activity between cells. Finally we will use techniques to show the molecular signals that change in injured cells when treated with this therapy so that we can target them directly with new drugs. This research will be important for developing therapeutic strategies for treating spinal injured patients.</gtr:abstractText><gtr:technicalSummary>There have been rapid and significant advances in the area of neurorestoration over the last decade or so, much of which has focussed on neuroprotection, neuroregeneration and adaptive plasticity. There is now a considerable optimism about translating this work into effective clinical therapies, particularly in the area of spinal cord injury where no restorative treatments are available. However, this drive towards therapy cannot proceed before some critical questions are addressed. These are: which of the strategies identified from basic neurobiological studies will be the most effective in the clinic? What mechanism can promote the greatest functional repair? How can a therapy best be applied in a clinical context?

This proposal seeks to undertake a series of linked and mutually interdependent studies in the field of spinal cord injury which will:

1) Characterise processes underlying spontaneous changes in conduction, recovery and remyelination in a clinically relevant chronic spinal cord injury.
2) Optimise delivery of one of the leading experimental strategies, the use of chondroitinase ABC, by developing novel lentriviral vectors.
3) Develop novel techniques to assess structural and functional remodelling of synapses after spinal cord injury. I will use these to quantitatively examine synaptic rearrangements that occur spontaneously after spnal cord injury and driven by interventions targeting chondroitin sulphate proteoglycans. I believe these techniques will find widespread application in this field.
4) Identify molecular mechanisms involved in chondroitinase ABC-mediated repair.</gtr:technicalSummary><gtr:fund><gtr:end>2018-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1913771</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>McGill University Health Centre</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>SCI-NET</gtr:description><gtr:id>28B21925-D5A3-4BE6-80E2-CAF2FA7ED941</gtr:id><gtr:impact>This multidisciplinary collaborative project combines basic and clinical approaches and innovative proteomics and glycomics technology with the aim of leading to new understanding of tissue remodelling after spinal cord injury, leading to novel therapeutic drug targets.</gtr:impact><gtr:outcomeId>581c6b436005c5.08795845-1</gtr:outcomeId><gtr:partnerContribution>This multi-disciplinary collaborative project combines basic and clinical approaches and innovative proteomics and glycomics technology with the aim of leading to new understanding of tissue remodelling.

McGill University, Quebec, Canada: mouse models to study inflammation after spinal cord injury. 
Charit&amp;eacute; -Universit&amp;auml;tsmedizin Berlin, Germany: clinical research - provide access to serum from spinal injured patients and CSF samples from the SCI-ential trial and the PROLONG trial.
ETH Zurich, Switzerland: analytical technologies and methods for the analysis of complex biological systems and the integration of -omics data by advanced bioinformatics methods; advanced mass spectrometry techniques, large-scale proteomics studies, label-free quantitative proteomics applications.</gtr:partnerContribution><gtr:piContribution>Identification of novel bioactive mediators of tissue scarring, inflammation and extracellular matrix remodeling after spinal cord injury.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Zurich</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Functional Genomics Centre Zurich (FGCZ)</gtr:department><gtr:description>SCI-NET</gtr:description><gtr:id>A8D7754C-E4DF-4BB5-9483-E3B58F018563</gtr:id><gtr:impact>This multidisciplinary collaborative project combines basic and clinical approaches and innovative proteomics and glycomics technology with the aim of leading to new understanding of tissue remodelling after spinal cord injury, leading to novel therapeutic drug targets.</gtr:impact><gtr:outcomeId>581c6b436005c5.08795845-3</gtr:outcomeId><gtr:partnerContribution>This multi-disciplinary collaborative project combines basic and clinical approaches and innovative proteomics and glycomics technology with the aim of leading to new understanding of tissue remodelling.

McGill University, Quebec, Canada: mouse models to study inflammation after spinal cord injury. 
Charit&amp;eacute; -Universit&amp;auml;tsmedizin Berlin, Germany: clinical research - provide access to serum from spinal injured patients and CSF samples from the SCI-ential trial and the PROLONG trial.
ETH Zurich, Switzerland: analytical technologies and methods for the analysis of complex biological systems and the integration of -omics data by advanced bioinformatics methods; advanced mass spectrometry techniques, large-scale proteomics studies, label-free quantitative proteomics applications.</gtr:partnerContribution><gtr:piContribution>Identification of novel bioactive mediators of tissue scarring, inflammation and extracellular matrix remodeling after spinal cord injury.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>California Institute of Technology</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Division of Chemistry and Chemical Engineering</gtr:department><gtr:description>A chemical approach to elucidating the structure-function relationships of chondroitin sulfate glycosaminoglycans</gtr:description><gtr:id>536C9533-0A3B-4214-BD2D-E0FA345946C7</gtr:id><gtr:impact>This is a multidisciplinary project, involving organic chemistry (Caltech) and Neurobiology (King's College London)</gtr:impact><gtr:outcomeId>581c64cad96cb6.66352218-1</gtr:outcomeId><gtr:partnerContribution>Design and development of novel small molecule sulfotransferase inhibitors.</gtr:partnerContribution><gtr:piContribution>The contribution of the Bradbury Lab to this collaboration is to assess novel compounds generated by the Hsieh-Wilson lab for efficacy in preventing the upregulation of inhibitory scar matrix in vivo and their potential for promoting neuroplasticity and tissue repair in experimental models of spinal cord injury.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International Spinal Research Trust (Spinal Research)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CHASE-IT</gtr:description><gtr:id>10142983-5927-49ED-916E-247D83061A71</gtr:id><gtr:impact>Multiple disciplines: viral vector development, molecular biology, whole animal in vivo systems, spinal cord injury repair.</gtr:impact><gtr:outcomeId>54633cc21a9a84.74531173-1</gtr:outcomeId><gtr:partnerContribution>The CHASE-IT consortium (chondroitinase for spinal injury therapy) aims to design an optimised safe vector for treatment of spinal cord injury. This a collaborative partnership between viral vector and molecular biology labs and in vivo spinal cord injury labs (Cambridge University, King's College London, Royal Holloway and the Netherlands Institute of Neuroscience).</gtr:partnerContribution><gtr:piContribution>Testing the efficacy of gene therapy for promoting repair and functional recovery in clinically relevant animal models of spinal cord injury.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Netherlands Institute for Neuroscience (NIN)</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>CHASE-IT</gtr:description><gtr:id>A1698881-C164-4A50-A203-3A80F9D66E7D</gtr:id><gtr:impact>Multiple disciplines: viral vector development, molecular biology, whole animal in vivo systems, spinal cord injury repair.</gtr:impact><gtr:outcomeId>54633cc21a9a84.74531173-3</gtr:outcomeId><gtr:partnerContribution>The CHASE-IT consortium (chondroitinase for spinal injury therapy) aims to design an optimised safe vector for treatment of spinal cord injury. This a collaborative partnership between viral vector and molecular biology labs and in vivo spinal cord injury labs (Cambridge University, King's College London, Royal Holloway and the Netherlands Institute of Neuroscience).</gtr:partnerContribution><gtr:piContribution>Testing the efficacy of gene therapy for promoting repair and functional recovery in clinically relevant animal models of spinal cord injury.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CHASE-IT</gtr:description><gtr:id>EF9DF8C3-4358-453C-8B70-757A7357968B</gtr:id><gtr:impact>Multiple disciplines: viral vector development, molecular biology, whole animal in vivo systems, spinal cord injury repair.</gtr:impact><gtr:outcomeId>54633cc21a9a84.74531173-2</gtr:outcomeId><gtr:partnerContribution>The CHASE-IT consortium (chondroitinase for spinal injury therapy) aims to design an optimised safe vector for treatment of spinal cord injury. This a collaborative partnership between viral vector and molecular biology labs and in vivo spinal cord injury labs (Cambridge University, King's College London, Royal Holloway and the Netherlands Institute of Neuroscience).</gtr:partnerContribution><gtr:piContribution>Testing the efficacy of gene therapy for promoting repair and functional recovery in clinically relevant animal models of spinal cord injury.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Charit? - University of Medicine Berlin</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SCI-NET</gtr:description><gtr:id>EB68876F-936A-4728-A68B-9C8ECBFA2564</gtr:id><gtr:impact>This multidisciplinary collaborative project combines basic and clinical approaches and innovative proteomics and glycomics technology with the aim of leading to new understanding of tissue remodelling after spinal cord injury, leading to novel therapeutic drug targets.</gtr:impact><gtr:outcomeId>581c6b436005c5.08795845-2</gtr:outcomeId><gtr:partnerContribution>This multi-disciplinary collaborative project combines basic and clinical approaches and innovative proteomics and glycomics technology with the aim of leading to new understanding of tissue remodelling.

McGill University, Quebec, Canada: mouse models to study inflammation after spinal cord injury. 
Charit&amp;eacute; -Universit&amp;auml;tsmedizin Berlin, Germany: clinical research - provide access to serum from spinal injured patients and CSF samples from the SCI-ential trial and the PROLONG trial.
ETH Zurich, Switzerland: analytical technologies and methods for the analysis of complex biological systems and the integration of -omics data by advanced bioinformatics methods; advanced mass spectrometry techniques, large-scale proteomics studies, label-free quantitative proteomics applications.</gtr:partnerContribution><gtr:piContribution>Identification of novel bioactive mediators of tissue scarring, inflammation and extracellular matrix remodeling after spinal cord injury.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Holloway, University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CHASE-IT</gtr:description><gtr:id>C494B612-70F4-4E7E-B68F-2400119758C8</gtr:id><gtr:impact>Multiple disciplines: viral vector development, molecular biology, whole animal in vivo systems, spinal cord injury repair.</gtr:impact><gtr:outcomeId>54633cc21a9a84.74531173-4</gtr:outcomeId><gtr:partnerContribution>The CHASE-IT consortium (chondroitinase for spinal injury therapy) aims to design an optimised safe vector for treatment of spinal cord injury. This a collaborative partnership between viral vector and molecular biology labs and in vivo spinal cord injury labs (Cambridge University, King's College London, Royal Holloway and the Netherlands Institute of Neuroscience).</gtr:partnerContribution><gtr:piContribution>Testing the efficacy of gene therapy for promoting repair and functional recovery in clinically relevant animal models of spinal cord injury.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>YouTube video abstract for BRAIN neuregulin paper</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BECF1D3E-F6E0-4F81-A187-4CC16C9B8F37</gtr:id><gtr:impact>Made a YouTube video abstract of our paper published in BRAIN &amp;quot;Neuregulin-1 controls an endogenous repair mechanism after spinal cord injury&amp;quot; to disseminate the findings wider and make accessible to a lay audience</gtr:impact><gtr:outcomeId>581c77ae18aa32.09088192</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.youtube.com/watch?v=DYyS7SveTG4</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Spinal Research interview for youtube</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9D3C0F89-0FEA-414C-8C42-E1406CB91E23</gtr:id><gtr:impact>Interviewed by the Spinal Research charity for a magazine article and subsequent youtube video on my lab's recent and particularly recent findings from my lab on a novel gene therapy for improving tissue pathology and restoring function after traumatic spinal cord injury</gtr:impact><gtr:outcomeId>56e1543a5af589.12738197</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:url>https://www.youtube.com/watch?v=R0NFioMnwN4</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Wings for Life launch of The World Run</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>60620651-5B78-4F64-B42E-040F109887DB</gtr:id><gtr:impact>Wings for Life launch of The World Run with Colin Jackson, King's College London. Hosted the launch of a major fundraising campaign by Wings for Life to raise money for spinal research; 50 guests (celebrity spinal research supporters and the media; spinal injured patients, lay public, charitable donors). Presentations by Head of Wings for Life, Colin Jackson, myself (on Spinal Cord Injury Repair, in lay terms) and a spinal injured patient, followed by media interviews and pictures, lab tours and demonstrations.


Hosted the launch of a major fundraising campaign by Wings for Life to raise money for spinal research; 50 guests (celebrity spinal research supporters and the media; spinal injured patients, lay public, charitable donors).

After the event and my presentation I have had many enquiries from spinal research supporters and charities about my research and the development of chondroitinase therapy towards the clinic</gtr:impact><gtr:outcomeId>546355747f6f70.15930661</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Spinal Research Supporters Evening</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B52B1A49-BC36-4B1F-B2C5-E50296710F1D</gtr:id><gtr:impact>Spinal Research Supporters Reception, King's College London. Hosted and organised the event for 120 guests (spinal research supporters, spinal injured patients and family, lay public, charitable donors, charitable foundations). Presentation of my research on &amp;quot;Spinal Cord Injury Repair&amp;quot; (in lay terms) to this audience, followed by lab tours and demonstrations, &amp;quot;meet the scientists&amp;quot; and poster presentations.

Spinal injury interest groups pushing for chondroitinase therapy to be translated towards a clinical therapy for spinal cord injury</gtr:impact><gtr:outcomeId>54635446594163.10404894</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:url>http://www.spinal-research.org/research/chondroitinase-becomes-research-focus/</gtr:url><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The Lancet Neurology Lifeline Column</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5345492B-1A53-491B-AC7B-EACC3FFB4FE4</gtr:id><gtr:impact>Featured interview for Lancet Neurology's &amp;quot;Lifeline&amp;quot; column: a series of questions on why I became a scientist, my biggest achievement, how would i improve public understanding of research etc</gtr:impact><gtr:outcomeId>56e14e45169eb3.36427744</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.thelancet.com/pdfs/journals/laneur/PIIS1474-4422(14)70276-5.pdf</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Wings for Life Supporters Evening</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EEADD67D-BDCE-4CE3-8051-8AE43D442390</gtr:id><gtr:impact>Wings for Life Supporters Evening, King's College London. Hosted and organised the event for 30 guests (spinal research supporters, spinal injured patients, charitable donors). Presentation of my research on &amp;quot;Spinal Cord Injury Repair&amp;quot; (in lay terms) to this audience, followed by lab tours and demonstrations, &amp;quot;meet the scientists&amp;quot; and poster presentations.


Following the meeting I have had many requests for information about my research and for translating promising experimental therapeutics to treat spinal cord injury.</gtr:impact><gtr:outcomeId>546356097885b5.84111088</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release for chondroitinase gene therapy paper</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>07B2F175-6568-457A-B0F5-C33F598AD45E</gtr:id><gtr:impact>Press coverage, press release and interviews with the media following publication of our findings on a novel &amp;quot;scar-busting gene therapy&amp;quot; for spinal cord repair</gtr:impact><gtr:outcomeId>56e14eee2c40b7.86725638</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.sfn.org/Press-Room/News-Release-Archives/2014/Gene-Therapy-Improves-Limb-Function-Following-Spinal-Cord-Injury</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release and media interviews for BRAIN paper</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F9DC69B8-0C7D-4EBF-AB9A-9D23A1FA5B5C</gtr:id><gtr:impact>Press release, coverage and interviews following neuregulin-1 publication in Brain: &amp;quot;Scientists pinpoint molecular signal that drives and enables spinal cord repair&amp;quot;</gtr:impact><gtr:outcomeId>581c76b2a6a180.65406449</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://medicalxpress.com/news/2016-03-scientists-molecular-enables-spinal-cord.html</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Participation in expert working group on large animal and primate models of spinal cord injury for the testing of novel therapies</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0D49856A-B942-4445-A06D-15BAF2948513</gtr:id><gtr:impact>Part of an expert working group regarding the use of large animal and primate models in the context of testing novel therapeutics for spinal cord injury. The role that such large animal and primate models should play in the translational pipeline is unclear. In this initiative we engaged members of the SCI research community in a questionnaire and round-table focus group discussion around the use of such models. Forty-one SCI researchers from academia, industry, and granting agencies were asked to complete a questionnaire about their opinion regarding the use of large animal and primate models in the context of testing novel therapeutics. Following further discussions of the survery outcomes a paper was written by the group highlighting the main findings.The group generally felt that large animal and primate models of SCI serve a potentially useful role in the translational pipeline for novel therapies, and that the rational use of these models would depend on the type of therapy and specific research question being addressed. While testing within these models should not be mandatory, the detection of beneficial effects using these models lends additional support for translating a therapy to humans. These models provides an opportunity to evaluate and refine surgical procedures prior to use in humans, and safety and bio-distribution in a spinal cord more similar in size and anatomy to that of humans</gtr:impact><gtr:outcomeId>56e14d54c58ba3.51404294</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2014,2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Rosetrees Trust Grant</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Rosetrees Trust</gtr:fundingOrg><gtr:fundingRef>JS16/M276</gtr:fundingRef><gtr:id>2712CEE0-5861-41E6-BF5B-7BE4B55A2957</gtr:id><gtr:outcomeId>fzcAXPWGF3t</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:currCode>CHF</gtr:currCode><gtr:currCountryCode>Switzerland</gtr:currCountryCode><gtr:currLang>it_CH</gtr:currLang><gtr:description>IrP Project Grant</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>International Foundation for Research in Paraplegia (IRP)</gtr:fundingOrg><gtr:fundingRef>P145</gtr:fundingRef><gtr:id>2C483122-D1CF-449B-A2A8-9F3996E5CDDE</gtr:id><gtr:outcomeId>54634ee70314e0.13968764</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Funding for Research</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>Morton Cure Paralysis Fund</gtr:fundingOrg><gtr:id>8E6EB8C4-9478-40CF-84EB-8694CD8A39EE</gtr:id><gtr:outcomeId>56e148ab7928a5.45164472</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>75000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ISRT Translational Grant</gtr:description><gtr:end>2015-02-02</gtr:end><gtr:fundingOrg>International Spinal Research Trust (Spinal Research)</gtr:fundingOrg><gtr:fundingRef>TR1004_01</gtr:fundingRef><gtr:id>741EFB24-6259-4477-BA4E-A2373B85B763</gtr:id><gtr:outcomeId>mMtC9BR7hDj</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>35000</gtr:amountPounds><gtr:country>Austria, Republic of</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>WfL Project Grant Year1</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>Wings for Life Spinal Cord Research Foundation</gtr:fundingOrg><gtr:fundingRef>WFL-GB-020/13</gtr:fundingRef><gtr:id>0DA2C993-6D97-45C1-B97F-4503551E9156</gtr:id><gtr:outcomeId>EkY38MGeYx5</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>101958</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Natalie Rose Barr Studentship</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>International Spinal Research Trust (Spinal Research)</gtr:fundingOrg><gtr:fundingRef>NRB113</gtr:fundingRef><gtr:id>9DA75B01-1A7E-44A0-959F-A714028EC367</gtr:id><gtr:outcomeId>56e14982409795.95385047</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>35000</gtr:amountPounds><gtr:country>Austria, Republic of</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>WfL Project Grant Year2</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>Wings for Life Spinal Cord Research Foundation</gtr:fundingOrg><gtr:fundingRef>WFL-GB-046/14</gtr:fundingRef><gtr:id>58A22139-3E06-4342-B2F2-72CCABE9E814</gtr:id><gtr:outcomeId>54634fedb8a054.78107981</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>229888</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>A chemical approach to elucidating the structure-function relationships of chondronitin sulfate glycosaminoglycans</gtr:description><gtr:end>2019-05-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:fundingRef>2RO1GM093627-05</gtr:fundingRef><gtr:id>955363FC-74B9-4210-A7DE-847468FF6E43</gtr:id><gtr:outcomeId>581c72139470e0.59103162</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>In collaboration with CHASE-IT consortia members we have designed and evaluated a novel gene therapy which promotes tissue repair and restores function in clinically relevant models of spinal cord injury. We are now designing a regulatable and safe version of this therapy for human use.</gtr:description><gtr:id>658F2903-7ECD-4906-AB5F-83F5B63B5A65</gtr:id><gtr:impact>Many labs have requested the vector we have been working on and it is now being used and assessed by other labs worldwide.</gtr:impact><gtr:outcomeId>56e15549739752.27574609</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Chondroitinase gene therapy for spinal cord injury</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Development of a model where we have determined functional, anatomical and pathological outcome measures for assessing loss of function following spinal cord injury and functional changes after therapeutic intervention - providing a robust tool for assessing the potential for promising experimental therapies to promote functional repair after spinal cord injury.</gtr:description><gtr:id>FA8DB068-FB28-43C5-8649-7B0F1A54D651</gtr:id><gtr:impact>Collaborations with other groups worldwide to assess promising experimental therapies, to enable robust pre-clinical data.</gtr:impact><gtr:outcomeId>565505712c4a04.45820193</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Clinically relevant model of spinal cord injury</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>8316BDC0-A85F-4C12-902E-81CD0F23F9F6</gtr:id><gtr:title>Regulation of IL-10 by chondroitinase ABC promotes a distinct immune response following spinal cord injury.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a9402a06420612620c53e91af3934ad"><gtr:id>6a9402a06420612620c53e91af3934ad</gtr:id><gtr:otherNames>Didangelos A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>doi_55f9859858fc25b6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4173AADC-C29B-4D10-8CA7-6EB234BAC387</gtr:id><gtr:title>Neuregulin-1 controls an endogenous repair mechanism after spinal cord injury.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83ff2192003df0441005cc67a9bdfc98"><gtr:id>83ff2192003df0441005cc67a9bdfc98</gtr:id><gtr:otherNames>Bartus K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>581c5d3af098c2.18670495</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49ADA22E-3869-43B3-8E62-E1ACA619B8AF</gtr:id><gtr:title>Restoring function after spinal cord injury: towards clinical translation of experimental strategies</gtr:title><gtr:parentPublicationTitle>The Lancet Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc7e9b9b6c2eaa7fc193ba9e4beda965"><gtr:id>fc7e9b9b6c2eaa7fc193ba9e4beda965</gtr:id><gtr:otherNames>Ramer L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54621e5eeb9602.37141308</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6740808-525B-49B0-B4AE-E9ECF7437219</gtr:id><gtr:title>Conduction failure following spinal cord injury: functional and anatomical changes from acute to chronic stages.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03e8a186efc2c3999987d8d9c65f0361"><gtr:id>03e8a186efc2c3999987d8d9c65f0361</gtr:id><gtr:otherNames>James ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>pm_14577_27_22171053</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B88CD474-2FAE-42F7-A5B3-E06C7C0FBD1A</gtr:id><gtr:title>Structural and Functional Substitution of Deleted Primary Sensory Neurons by New Growth from Intrinsic Spinal Cord Nerve Cells: An Alternative Concept in Reconstruction of Spinal Cord Circuits.</gtr:title><gtr:parentPublicationTitle>Frontiers in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03e8a186efc2c3999987d8d9c65f0361"><gtr:id>03e8a186efc2c3999987d8d9c65f0361</gtr:id><gtr:otherNames>James ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-2295</gtr:issn><gtr:outcomeId>5a2fd49c8269d8.02757628</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5B97858-5FFA-47C2-BD95-F1B4C6C85477</gtr:id><gtr:title>Chondroitinase gene therapy improves upper limb function following cervical contusion injury.</gtr:title><gtr:parentPublicationTitle>Experimental neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03e8a186efc2c3999987d8d9c65f0361"><gtr:id>03e8a186efc2c3999987d8d9c65f0361</gtr:id><gtr:otherNames>James ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0014-4886</gtr:issn><gtr:outcomeId>565502f246c034.14125644</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1625E627-4104-4095-AE91-492D66149317</gtr:id><gtr:title>Large-scale chondroitin sulfate proteoglycan digestion with chondroitinase gene therapy leads to reduced pathology and modulates macrophage phenotype following spinal cord contusion injury.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83ff2192003df0441005cc67a9bdfc98"><gtr:id>83ff2192003df0441005cc67a9bdfc98</gtr:id><gtr:otherNames>Bartus K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>54621dc6bff832.16064787</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAEE170D-C462-4BE8-A5DF-96F002DFD6F4</gtr:id><gtr:title>Delayed treatment with chondroitinase ABC reverses chronic atrophy of rubrospinal neurons following spinal cord injury.</gtr:title><gtr:parentPublicationTitle>Experimental neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0684ff0a808a8056441bb17890a5be0d"><gtr:id>0684ff0a808a8056441bb17890a5be0d</gtr:id><gtr:otherNames>Carter LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0014-4886</gtr:issn><gtr:outcomeId>FG2o2qJhLPE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D98D78F8-8EFF-49F0-88F0-8EC997567657</gtr:id><gtr:title>Chondroitinase ABC promotes compensatory sprouting of the intact corticospinal tract and recovery of forelimb function following unilateral pyramidotomy in adult mice.</gtr:title><gtr:parentPublicationTitle>The European journal of neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a03d392a595ce88516148d840751941"><gtr:id>8a03d392a595ce88516148d840751941</gtr:id><gtr:otherNames>Starkey ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0953-816X</gtr:issn><gtr:outcomeId>pm_14577_27_23061434</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E33A68DA-CA56-4312-A605-39D1B14BB671</gtr:id><gtr:title>High-throughput proteomics reveal alarmins as amplifiers of tissue pathology and inflammation after spinal cord injury.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a9402a06420612620c53e91af3934ad"><gtr:id>6a9402a06420612620c53e91af3934ad</gtr:id><gtr:otherNames>Didangelos A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56e145b520ff05.20977421</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1002055</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>